185 related articles for article (PubMed ID: 17194480)
21. Comment on Neumann et al. 'Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients'.
D'Offizi G; Martini F; Rozera G; Abbate I; Capobianchi MR; Narciso P; Dianzani F
AIDS; 2008 Jan; 22(2):321. PubMed ID: 18097242
[No Abstract] [Full Text] [Related]
22. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
[TBL] [Abstract][Full Text] [Related]
23. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
Bräu N
Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
[TBL] [Abstract][Full Text] [Related]
24. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
[TBL] [Abstract][Full Text] [Related]
26. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
27. Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study.
Michielsen P; Bottieau E; Van Vlierberghe H; Van Marck E; Vandemaele E; Denys M; Brasseur JP; Popan M;
Acta Gastroenterol Belg; 2009; 72(4):389-93. PubMed ID: 20163031
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of hepatitis C virus infection in patients with concurrent human immunodeficiency virus infection].
Peters L; Lindhardt BØ
Ugeskr Laeger; 2006 Oct; 168(42):3604-8. PubMed ID: 17069721
[TBL] [Abstract][Full Text] [Related]
29. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
[TBL] [Abstract][Full Text] [Related]
30. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
31. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
[TBL] [Abstract][Full Text] [Related]
32. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection.
Lissen E; Clumeck N; Sola R; Mendes-Correa M; Montaner J; Nelson M; DePamphilis J; Pessôa M; Buggisch P; Main J; Dieterich D
AIDS; 2006 Nov; 20(17):2175-81. PubMed ID: 17086057
[TBL] [Abstract][Full Text] [Related]
33. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
Voigt E; Schulz C; Klausen G; Goelz J; Mauss S; Schmutz G; Jessen H; Weitner L; Mutz A; Schranz D; Rockstroh JK;
J Infect; 2006 Jul; 53(1):36-42. PubMed ID: 16269184
[TBL] [Abstract][Full Text] [Related]
34. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
[TBL] [Abstract][Full Text] [Related]
35. Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.
Pau AK; McLaughlin MM; Hu Z; Agyemang AF; Polis MA; Kottilil S
AIDS Patient Care STDS; 2006 Sep; 20(9):612-9. PubMed ID: 16987047
[TBL] [Abstract][Full Text] [Related]
36. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
Poynard T; McHutchison J; Manns M; Myers RP; Albrecht J
Hepatology; 2003 Aug; 38(2):481-92. PubMed ID: 12883493
[TBL] [Abstract][Full Text] [Related]
37. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy.
Bagheri H; Fouladi A; Barange K; Lapeyre-Mestre M; Payen JL; Montastruc JL; Vinel JP
Pharmacotherapy; 2004 Nov; 24(11):1546-53. PubMed ID: 15537560
[TBL] [Abstract][Full Text] [Related]
38. HCV infection in the setting of HIV: prevalence, disease, treatment.
Laurence J
AIDS Read; 2006 Mar; 16(3):115-6. PubMed ID: 16538952
[No Abstract] [Full Text] [Related]
39. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients.
Mukherjee S; Lyden E; McCashland TM; Schafer DF
J Gastroenterol Hepatol; 2005 Feb; 20(2):198-203. PubMed ID: 15683421
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerance of HCV treatment in HIV-HCV coinfected patients: the potential interaction of PI treatment.
Poizot-Martin I; Marimoutou C; Benhaim S; Drogoul-Vey MP; Dinh T; Vion-Dury F; Frixon-Marin V; Tamalet C; Gastaut JA
HIV Clin Trials; 2003; 4(4):262-8. PubMed ID: 12916012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
